196 related articles for article (PubMed ID: 34467576)
1. State-of-the-art cytology of pleural fluid, focusing on the diagnosis of mesothelioma.
Monaco SE; Brcic L; Dacic S
Cytopathology; 2022 Jan; 33(1):57-64. PubMed ID: 34467576
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in the Diagnosis of Malignant Mesothelioma: Focus on Approach in Challenging Cases and in Limited Tissue and Cytologic Samples.
Monaco S; Mehrad M; Dacic S
Adv Anat Pathol; 2018 Jan; 25(1):24-30. PubMed ID: 29227332
[TBL] [Abstract][Full Text] [Related]
3. An Updated Contextual Approach to Mesothelial Proliferations in Pleural Effusion Cytology Leveraging Morphology, Ancillary Studies, and Novel Biomarkers.
Miller LJ; Holmes IM; Lew M
Arch Pathol Lab Med; 2024 Apr; 148(4):409-418. PubMed ID: 37622452
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations.
Chapel DB; Husain AN; Krausz T
Mod Pathol; 2019 Mar; 32(3):376-386. PubMed ID: 30315275
[TBL] [Abstract][Full Text] [Related]
5. Highlights of the 14th international mesothelioma interest group meeting: Pathologic separation of benign from malignant mesothelial proliferations and histologic/molecular analysis of malignant mesothelioma subtypes.
Churg A; Nabeshima K; Ali G; Bruno R; Fernandez-Cuesta L; Galateau-Salle F
Lung Cancer; 2018 Oct; 124():95-101. PubMed ID: 30268487
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
7. Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I; Myers J
Acta Med Acad; 2021 Apr; 50(1):197-208. PubMed ID: 34075773
[TBL] [Abstract][Full Text] [Related]
8. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
9. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey.
Paintal A; Raparia K; Zakowski MF; Nayar R
Cancer Cytopathol; 2013 Dec; 121(12):703-7. PubMed ID: 24039177
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
[TBL] [Abstract][Full Text] [Related]
11. Advances in pathological diagnosis of mesothelioma: what pulmonologists should know.
Louw A; Badiei A; Creaney J; Chai MS; Lee YCG
Curr Opin Pulm Med; 2019 Jul; 25(4):354-361. PubMed ID: 31169558
[TBL] [Abstract][Full Text] [Related]
12. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Berg KB; Dacic S; Miller C; Cheung S; Churg A
Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
[TBL] [Abstract][Full Text] [Related]
13. Reliably making the primary diagnosis of mesothelioma utilizing serous fluid cytology specimens: an institutional experience.
Jones TE; Geisler DL; Baskota SU; Ohori NP; Cuda J; Khader SN
J Am Soc Cytopathol; 2024; 13(3):174-182. PubMed ID: 38514361
[TBL] [Abstract][Full Text] [Related]
14. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
15. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
Kulduk G; Ekinci Ö; Toker G; Demirci U; Özaydın E; Akyürek N; Memiş L
Pathol Res Pract; 2019 Jun; 215(6):152377. PubMed ID: 30885529
[TBL] [Abstract][Full Text] [Related]
16. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
[TBL] [Abstract][Full Text] [Related]
17. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
18. Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
Hiroshima K; Wu D; Hasegawa M; Koh E; Sekine Y; Ozaki D; Yusa T; Walts AE; Marchevsky AM; Nabeshima K; Tada Y; Shimada H; Tagawa M
Diagn Cytopathol; 2016 Jul; 44(7):591-8. PubMed ID: 27079839
[TBL] [Abstract][Full Text] [Related]
19. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
20. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
